Roche and Janus partner to develop TLR inhibitor for autoimmune diseases

TLRs are said to be important class of proteins that play a crucial role in the innate immune system and scientific evidence links aberrant TLR activation and signaling with the development of autoimmune disorders.

Under the deal, both firms will work exclusively on TLR research and development.

Janus Biotherapeutics co-founder and CEO Joseph Baron said: "We are delighted to have found a partner with the capability to fully leverage our team’s world class expertise in TLR biology and chemistry.

"We hope that this collaboration will ultimately benefit patients with autoimmune diseases and look forward to working with Roche on our shared goal to develop innovative medicines."

As per terms of the deal, Janus will secure an upfront cash payment and R&D funding over a collaboration period.

Roche will be provided an option to acquire Janus, based on the achievement of certain predetermined milestones.

Janus’ shareholders will be eligible to secure an acquisition fee and potentially, development milestones, in the event that the option is exercised.

Janus Biotherapeutics co-founder and chief scientific officer Grayson Lipford said: "Even if still in a preclinical phase, Janus’ unique triple TLR antagonist has potential therapeutic applications across multiple autoimmune diseases with high unmet medical need."